The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for hepatitis C virus-related compensated cirrhosis with osteoporosis
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Eldecalcitol (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Osteoporosis
- Focus Therapeutic Use
- Acronyms CHALLENGE D trial
- 03 Jan 2017 New trial record